Company ProfilePremium

PuraPharm Corporation Limited

Company Profile Analysis

Ticker: 1498.HK培力農本方有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
PuraPharm Corporation Limited - Company showcase

Year Founded & Workforce

1998

460 Employees

PuraPharm Corporation Limited logo

PuraPharm Corporation Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

PuraPharm Corporation Limited Overview

PuraPharm is a founder-controlled Hong Kong Chinese-medicine company. It built its franchise on concentrated Chinese medicine granules (CCMG), sold under the Nong's® (農本方) brand. CCMG are modern, instantly soluble extracts that replace the traditional practice of boiling raw herbs. The group is vertically integrated. It runs herb plantations in Guizhou, a GMP/TGA/PIC/S-certified extraction plant in Nanning, a CNAS ISO 17025 laboratory, and distribution to Hong Kong hospitals, NGOs and private practitioners. It also operates 22 Nong's clinics in Hong Kong and a small Shenzhen network. It claims more than 80% share of Hong Kong's CCMG market, and that market now generates most of its profit. Its former growth engine, Mainland China CCMG, has effectively collapsed to zero external sales since national standards took effect in November 2021. Revenue has roughly halved since FY2021. The group has lost money for five consecutive years and carries HK$314M of debt against HK$12M of cash. It is a niche quality leader operating under a going-concern cloud.


Company's own description (paraphrased from AR2025 Corporate Profile)

The company describes itself as a leading Hong Kong-based Chinese medicine group. Its main activities are the research, development, production, marketing and sale of CCMG products under the Nong's® brand. It states that it is one of only five licensed CCMG manufacturers in China and the only non-PRC company licensed by the CFDA (now NMPA) to make and sell CCMG there. Its in-house CNAS ISO 17025 laboratory issues safety reports recognised in more than 70 countries. It has supplied CCMG to most Hong Kong hospitals and healthcare institutions with TCM clinics since 2004. It describes itself as the largest CCMG supplier in Hong Kong and a leading Chinese medicine clinic chain there. It also markets over-the-counter health brands: PuraGold®, Oncozac®, Immuzac® and Haveron®.

The filings describe the group's principal activities as:

  • R&D, production and sale of CCMG and Chinese healthcare products

  • plantation and trading of raw Chinese herbs

  • manufacture and sale of TCM decoction pieces (中藥飲片)

  • Chinese medical diagnostic services

(FY25 Ann. note 1; IR26 note 1)

Independent characterisation

Revenue typeHKD K% of total
Sale of CCMG products and raw Chinese herbs230,67368.6
Sale of Chinese healthcare products92,55727.5
Rendering of diagnostic services12,8833.8
Total336,113100.0

In economic terms PuraPharm today is a Hong Kong CCMG distributor and manufacturer with a captive Mainland factory, plus three adjacent and much less profitable businesses: consumer health supplements, clinics, and upstream herbs. The key analytical point is that the "China CCMG and plantation" segment generated only HK$1k of external revenue in FY2025. Yet it booked HK$176.0M of inter-segment sales and a segment profit of HK$20.2M (FY25 Ann. note 3). The Nanning/Guizhou asset base now functions mainly as the manufacturing and supply hub for Hong Kong sales. That base accounts for the bulk of PP&E (HK$265.5M) and of RMB-denominated debt (HK$267.2M of HK$323.8M borrowings).

Business model and revenue mix (FY2025, FY25 Ann. note 4):

Product vs service: 96.2% of revenue is product sales recognised at a point in time. 3.8% is diagnostic services recognised over time. There is no subscription or licensing revenue. The clinic management system, CMCMS/TCMA 3.0, supports the clinics and is not reported as a separate revenue line.

Value chain position: fully integrated, from cultivation (Guizhou) through extraction and granulation (Nanning, plus pilot plants in Osaka and California), testing (CNAS lab), B2B distribution (HK hospitals, NGOs, private practitioners) and B2C retail (Nong's clinics, pharmacies, cross-border e-commerce).

Customer types: Hong Kong public hospitals and NGO-run TCM clinics, private Chinese medicine practitioners, retail consumers (clinic patients, drugstore and convenience-store buyers, online buyers in Mainland China), and US/European distributors and practitioners (KAN Herb). Mainland hospitals were historically a key channel but are being deliberately de-emphasised.

End-markets: Hong Kong prescription TCM; Mainland China TCM (now via private clinics and cross-border e-commerce); US/European herbal practitioner markets; Japanese health-food market.

Strategy

Stated strategy (AR2025 Chairman's Statement; reiterated in IR26, paraphrased)

  1. Shift from public hospital channels to private healthcare. Reduce reliance on Mainland public-hospital procurement; expand into private hospitals, clinics and direct-to-consumer.

  2. Expand Nong's® clinics in the Greater Bay Area. Grow the Shenzhen network and explore a franchise model under strict capital discipline. Note that the network contracted from 4 to 2 clinics in H1 2026.

  3. Accelerate cross-border e-commerce for healthcare products. Increase digital marketing to capture Mainland demand for premium Hong Kong-branded products.

  4. Strengthen international expansion. Use the US and Japanese plants to develop products for Canada, the USA, Japan, Southeast Asia, Australia and Korea (AR2025 Prospects).

The mission statement is about extending healthy, happy lives through the modernisation of Chinese medicine. The stated aim is to become the most admired herbal medicine company (AR2025).

Strategic initiatives in the last 24 months

InitiativeDateDetailStatus
Capital reductionQ1 2025Par value cut from US$0.1 to US$0.001; HK$303.8M offset against accumulated losses, enabling future dividend capacity and share issuance below old parCompleted
Patent Licence Agreement (connected)Signed 25 Jul 2025; completed 30 Oct 202593.5M shares at HK$0.43 (HK$40.2M) for patent rights; supports a clinical-trial pipeline across HK, Canada and the USCompleted; trials unfunded beyond HK$19.8M
Providence Discovery Fund subscriptionSigned 25 Jul 2025; completed 30 Oct 202546.5M shares at HK$0.43, raising HK$20.0M gross / HK$19.8M net; Dong Zimeng joins the boardCompleted; proceeds unutilised at end-2025
Convertible bondSigned 26 Feb 2026; completed 23 Mar 2026HK$20M, 6% coupon, 2-year (extendable to 3), conversion at HK$0.49. Proceeds: HK$10M working capital, HK$5M debt repayment, HK$4.85M production upgrade and CCMG R&D.HK$15M used by 30 Jun 2026
GBA clinic expansion and franchise2023–20261 Shenzhen clinic (2023), 3 (2024), 4 (2025), 2 (Jun 2026)Contracting
Cross-border e-commerce push2025–2026Higher A&P spend; H1 2026 S&D +33.4%Sales −20.4% in H1 2026
Cost programme2023–2026Headcount 662 to 441; S&D −76% since FY2021; H1 2026 admin −20.8%Ongoing; no formal savings target disclosed
Debt reduction and refinancingOngoingBorrowings HK$385M (FY23) to HK$314M (Jun 2026); loan-term deferrals negotiatedOngoing
ESG climate targets2030 vs 2020 baselineReductions in GHG, energy, water and waste intensity. Percentage targets not captured in the reviewed extract. Solar panels planned.Intensity rose in FY2025

Medium-term targets and guidance

Management provides no quantitative financial guidance or medium-term targets. The outlook language describes "measured optimism" for H2 2026 (IR26). Going-concern plans refer to restructuring the product mix, cost control, drawing and renewing bank facilities, finding new financing, and seeking investors (IR26 note 2).

Products & Services

Pricing models are not publicly disclosed for any product line.

Hong Kong / China CCMG (Nong's® professional range)

Product / lineDescription and specificationsTarget customerLaunch / latestSource
Nong's® CCMG single-herb granulesHerbs extracted via dynamic fluid extraction, low-temperature concentration and spray/freeze/vacuum/fluid-bed drying. Designed to match decoction efficacy, taste and aroma and to dissolve instantly. Tested for heavy metals, pesticides and microbes using DNA fingerprinting, FTIR and UHPLC.Hospitals, NGO clinics, private practitionersSince 2004 in HK hospitalsAR2025
Nong's® CCMG combination formulaeClassical multi-herb formulae; part of the >600 professional SKUs. The group cites its 2002 NATCM combo-formula research mandate.SameOngoingAR2025
Radix Astragali Formula GranulesVerified under the USP Dietary Ingredient Verification Program.Practitioners, exportUSP-verified 2014AR2025
Qing Fei Pai Du Tang granulesCOVID-19 formula recommended nationally by NATCM; emergency approval for the Nanning plant.PRC hospitalsFeb 2020AR2025
Kang Fu Yi Hao Fang granulesCOVID-19 recovery formula; emergency approval.PRC hospitalsFeb 2020AR2025
TCM decoction pieces (中藥飲片) and raw herbsGuizhou plantation, which claims supply of 500+ herb varieties; mainly internal supply.Group factories, tradersSince 2017 acquisitionAR2025 ESG; FY25 Ann.

Chinese Healthcare Products (OTC / consumer)

Brand / productDescriptionTargetLaunch / latestSource
Oncozac® (安固生®)Sole active ingredient ONCO-Z® Coriolus versicolor (Yunzhi) extract. Claimed as the first TCM ingredient verified by the USP Dietary Ingredient Verification Program. Supported by the "Living with Cancer" TV commercial (2023 Cannes finalist).Cancer patients and carers; consumersUSP-verified 2009; campaign 2023AR2025
PuraGold® (金靈芝®)Lingzhi (reishi) health product line; trademark registered. Detailed specifications not disclosed.Consumers (HK and overseas)—AR2025
Immuzac® (益抗適®)Immune-support product developed with proprietary research technology.Consumers—AR2025
Immuzac+™Immuzac® fortified with vitamin C; manufactured in Japan (SODX).Consumers2,020AR2025
Haveron® (烏髮濃®)Hair-health OTC product; specifications not disclosed.Consumers—AR2025
Nong's® OTC Formula rangeClassical formulae in consumer packaging; repackaged in 2019.Consumers via pharmaciesRepackaged 2019AR2025
Nong's® OTC Chinese Medicine CapsulesRange of ten capsule products for general relief and wellbeing.Consumers2,019AR2025
Nong's® "indigenous herbs" health foods"Homology of medicine and food" products applying TCM "four natures / five flavours" theory.Consumers2,021AR2025
Nong's® Instant Herbal DrinksSelf-Heal Plant, Monk Fruit and Wolfberry; sold in drugstore and convenience chains; TV commercial support.Younger consumersSep 2023AR2025
KAN® herbal formulasMore than 300 herbal formula products, manufactured at Kan Herb Company's GMP facility in California.US/European distributors and practitionersAcquired Mar 2017AR2025
SODX health foodsAntioxidants, fermented health foods and propolis products in granule, tablet and capsule forms; Health Food GMP pilot factory in Osaka.Japanese market; OEMAcquired Aug 2017AR2025

Clinics and services

OfferingDescriptionSource
Nong's® Chinese medicine clinics22 clinics in Hong Kong, mostly in shopping malls. 2 in Shenzhen at 30 Jun 2026, down from 4 at end-2025. Staffed by registered, university-trained CMPs who prescribe Nong's CCMG. Services include consultation, acupuncture and cupping.AR2025; IR26
Central flagship acupuncture centreHong Kong's largest clinic-grade acupuncture centre (per the company), targeting higher-spending customers.FY22 Ann.; AR2025
Integrated mammary gland centreFirst private integrated Chinese–Western centre for mammary disease in HK (50th clinic). Current status not disclosed.AR2025
CMCMS / TCMA 3.0Patented, automated clinic and hospital management and dispensing system. Version 3.0 (cloud-based, real-time sync, consultation analytics) rolled out July 2021.AR2025
Testing servicesCNAS ISO 17025 laboratory issuing safety reports recognised in 70+ countries. Mainly internal; external revenue not disclosed.AR2025

Pipeline / development assets

AssetStatusSource
Ren Shu Chang Le Granules (仁朮腸樂顆粒), IBSPhase 2 clinical trial entered in 2018. HK$6.4M of IPO proceeds remains unutilised, of which HK$4.3M is earmarked for it; expected use by December 2026.AR2025; FY25 Ann.
Patents licensed in Oct 2025 (Patent Licence Agreement; licensor identified in IR26 as BAGI Research Limited)Valued at HK$40.2M and paid in shares. Providence subscription proceeds (HK$19.8M) are earmarked for HK Phase 1–3 trials and NDA, Canadian Class 3 Natural Health Product registration, and US toxicology/IND. The therapeutic subject of the patents is not identified in the materials reviewed.FY25 Ann.; IR26 note 15
Two new proprietary Chinese medicines (IPO use of proceeds)Delayed; R&D taking longer than expected.FY25 Ann.

Financial Narrative

All figures are HK$ million unless stated. Sources: FY22, FY24 and FY25 Announcements (audited) and SA for derived operating income. EBITDA is analyst-computed as pre-tax loss + finance costs + depreciation of PP&E + depreciation of right-of-use assets + amortisation of intangibles. It includes impairments and fair-value losses.

Margins (%, analyst-computed)

Revenue CAGR FY2021–FY2025 (4 years): −15.5% (analyst-computed). FY2018 peak revenue of HK$745.5M to FY2025 is a 7-year CAGR of about −10.7%.

Major non-cash items (HK$ M):

  • FY2021: goodwill impairment 67.3; biological-asset fair-value loss 47.5; receivable impairment 17.0

  • FY2022: biological-asset loss 36.7; receivable impairment 10.5

  • FY2023: biological-asset loss 16.8; PP&E impairment 12.8; goodwill impairment 3.0

  • FY2024: PP&E/ROU impairment 2.4

  • FY2025: reversal of receivable impairment +8.2; ROU impairment 1.3

Balance sheet

30 June 2026 (IR26):

  • Total assets: 699.8

  • Cash: 12.2

  • Borrowings: 314.4 (current 272.8, non-current 41.6)

  • Convertible bonds: 19.5

  • Leases: 36.7

  • Equity: 125.0

  • Net current liabilities: 256.8

The FY2025 jump in intangibles to HK$67.0M reflects the patent rights acquired for HK$40.2M in shares (IR26 note 15).

Cash flow

Sources: filed cash-flow statements. FY2025 capex and intangible additions are from SA/S&P because the FY25 Ann. extract does not itemise investing flows; H1 2025 showed nil PP&E purchases. H1 2026 operating cash flow was −HK$1.3M, versus +HK$31.9M in H1 2025 (IR26).

Ratios (analyst-computed)

The company's own gearing ratio (borrowings ÷ equity) was 1.2 (FY2021), 1.8, 2.5, 3.1 and 2.5 (FY2025), and 2.5 at 30 Jun 2026 (company filings).

Commentary on trends, inflections and drivers

Revenue. The defining inflection is November 2021. Mainland national CCMG standards came into force at a time when only a limited number of standards existed: 342 by end-2024 and 396 by end-2025, against roughly 500 varieties typically needed by hospitals (FY24/FY25 Ann.). Hospitals stocked up ahead of the change and prices reset higher. PuraPharm's Mainland CCMG revenue went from HK$353.0M (FY2021) to HK$117.8M, HK$50.8M, HK$24.8M and effectively zero in FY2025, as management actively "downplayed" hospital channels. Hong Kong held up well through FY2024, helped by pricing gains and NGO and private-practitioner wins. In FY2025 it fell 7.4% on weaker local consumption and competition, then grew 2.0% in H1 2026.

Gross margin. Margin compressed from 64.2% to the low-50s as the high-margin Mainland business disappeared and standards-compliant production raised costs. It has been stable at about 53–54% for three years and reached 57.8% in H1 2026, helped by production-cost control (IR26).

Operating costs. Management has cut selling and distribution expenses by 76% since FY2021 (HK$220.0M to HK$52.5M) and reduced headcount by 35% (675 to 441). Administrative costs have proved stickier at about HK$152–172M, partly because R&D, clinic rents and Nanning's fixed overhead sit there. H1 2026 administrative expenses fell 20.8% to HK$68.3M, the most significant cost step in two years. Advertising rose 33% to support healthcare products, but healthcare product sales still fell 23.4%.

Below the line. Finance costs remain about 6% of revenue (HK$20.7M in FY2025) and absorb most of the segment profit. The FY2021–FY2023 losses were heavily driven by non-cash write-downs on the Guizhou plantation (biological assets, PP&E, goodwill), which totalled more than HK$200M across the three years. These are now exhausted. The residual loss of about HK$35M per year in FY2024–FY2025 is structural: segment profit of about HK$60–70M does not cover corporate overhead (about HK$74M) plus non-lease interest (about HK$20M).

Cash flow and balance sheet. Working-capital release funded about HK$200M of debt reduction between FY2021 and FY2025. Receivables fell from HK$261M to HK$56M and inventories from HK$166M to HK$99M; total borrowings fell from HK$499.7M to HK$323.8M. This tailwind is largely spent. FY2025 operating cash flow fell to HK$28.5M as payables were paid down (bills payable eliminated), and H1 2026 operating cash flow turned negative. Equity was replenished in FY2025 by HK$60.2M of share issuance (HK$40.2M of it non-cash, for patents). The current ratio of 0.47 and the reliance on rolling RMB bank lines are the central financial risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (Latest Name) Overview

Segment (latest name)ContentsKey products/services

Hong Kong (and overseas) CCMG

CCMG sales in HK, excluding sales through own clinics

Nong's® single and combination granules (>600 SKUs) sold to hospitals, NGOs and private practitioners

Chinese Healthcare Products

Production and sale of health products in HK, Mainland, USA and Japan

PuraGold®, Oncozac®, Immuzac®/Immuzac+™, Haveron®, Nong's OTC capsules and instant drinks, KAN formulas (US/EU), SODX health foods (Japan)

Clinics

Diagnostic services and CCMG dispensing in own clinics

22 HK Nong's clinics; 2 Shenzhen clinics (Jun 2026)

China CCMG and Plantation

Mainland CCMG production and sale; herb plantation and trading; decoction pieces

Nanning plant, Guizhou plantation; now mostly inter-segment supply

Revenue by Segment

Segment (HKD Mn, external revenue)FY2021FY2022FY2023FY2024FY2025

Hong Kong CCMG

162.7192.1208.4207.6192.3

Chinese Healthcare Products

78.178.982.084.392.6

Clinics

50.046.153.756.351.2

China CCMG

353.0117.850.824.8—

Plantation

15.713.311.99.1—

China CCMG and Plantation combined

368.7131.062.733.90.0

Total Group

659.6448.1406.9382.1336.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment by Segment Result

Segment result (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Hong Kong CCMG

41.154.074.768.747.2

Chinese Healthcare Products

9.3-2.0-16.49.61.7

Clinics

-8.0-5.71.20.1-9.6

China CCMG

61.9-23.2-12.4-0.1—

Plantation

-141.9-54.1-47.4-8.3—

China CCMG and Plantation combined

-79.9-77.4-59.8-8.420.2

Total segment result

-37.6-31.1-0.370.059.5

Segment margin (%)

Segment margin (%)FY2021FY2022FY2023FY2024FY2025

Hong Kong CCMG

25.328.135.833.124.5

Chinese Healthcare Products

11.9-2.5-20.011.41.8

Clinics

-16.0-12.42.20.2-18.8

Segment Revenue

SegmentFY2025 HKD K% of totalFY2024 HKD K% of totalYoY %

HK CCMG

192,31757.2207,59154.3-7.4

Healthcare products

92,55727.584,30222.1+9.8

Clinics

51,23815.256,31314.7-9.0

China CCMG and plantation

10.033,8848.9-100.0

Total

336,113100382,090100-12.0

Segment Revenue (Half-Yearly)

SegmentH1 2026 rev. HKD KH1 2025 rev. HKD KYoY %H1 2026 resultH1 2025 result

HK and overseas CCMG

93,91492,103+2.016,65542,802

Healthcare products

40,36852,699-23.45,98011,989

Clinics

24,54125,765-4.8-4,967-2,578

China CCMG and plantation

8501,728-50.810,006-12,929

Total

159,673172,295-7.327,67439,284

Income Statement and Per-Share Data

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

659.6448.1406.9382.1336.1

Cost of sales

236.2185.4190.2176.9156.0

Gross profit

423.4262.7216.6205.1180.2

Selling and distribution expenses

220.0157.491.764.952.5

Administrative expenses

168.5157.9171.5159.5152.1

Operating income (SA definition)

15.1-68.3-53.2-18.3-16.2

Finance costs

27.024.227.423.720.7

D&A (PP&E + ROU + intangibles)

50.148.748.654.644.5

EBITDA (analyst-computed, incl. impairments)

-40.0-46.3-26.349.230.8

Pre-tax income

-117.2-119.2-102.3-29.1-34.4

Income tax expense

4.71.03.86.30.8

Net income attributable

-121.9-120.2-106.1-35.4-35.2

EPS basic and diluted (HK cents)

-30.95-30.47-26.85-8.97-8.41

Dividend per share (HKD)

00000

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

64.258.653.253.753.6

Operating margin (SA op. income)

2.3-15.2-13.1-4.8-4.8

EBITDA margin

-6.1-10.3-6.512.99.2

Net margin

-18.5-26.8-26.1-9.3-10.5

S&D expense / revenue

33.435.122.517.015.6

Balance Sheet

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

1,205.91,016.5844.0715.7693.8

Cash and cash equivalents

59.775.820.112.816.2

Restricted cash and pledged deposits

25.431.227.125.55.0

Bank and other borrowings — current

407.7410.1304.0250.5268.3

Bank and other borrowings — non-current

92.048.781.189.255.5

Total borrowings

499.7458.8385.1339.7323.8

Lease liabilities

32.344.339.724.027.3

Net debt (borrowings − cash)

440.0383.0365.0326.9307.6

Total equity

401.6258.3153.2111.2130.5

Goodwill

21.021.017.917.917.9

Other intangible assets

41.137.634.731.667.0

Inventories

166.0172.4175.6123.699.2

Trade and bills receivables

261.4131.980.957.556.4

Trade and bills payables

140.7137.9146.4132.285.2

Working capital (net current assets)

-54.5-179.4-221.5-222.6-252.3

Cash Flow

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

-14.588.579.6104.028.5

Capex (purchase of PP&E)

3.120.819.214.80.3

Additions to intangibles

3.51.92.51.62.6

Free cash flow (OCF − PP&E capex)

-17.667.760.489.228.2

Lease principal paid

33.719.021.918.818.4

FCF after leases

-51.348.638.570.49.8

Dividends paid

00000

Share buybacks

00000

Cash equity issued

00.80020.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%, avg equity; FY2021 on year-end equity)

-30.4-36.4-51.6-26.8-29.1

ROA (%, avg assets; FY2021 on year-end assets)

-10.1-10.8-11.4-4.5-5.0

Pre-tax ROIC (%, SA op. income ÷ equity + debt + leases − cash)

1.7-10.0-9.5-3.9-3.5

Current ratio (x)

0.920.730.610.550.47

Debt / equity (x, borrowings ÷ equity)

1.241.782.513.052.48

Net debt / EBITDA (x; 0 = not meaningful, negative EBITDA)

0006.610.0

Interest coverage (x, SA op. income ÷ finance costs)

0.56-2.82-1.94-0.77-0.78

Asset turnover (x)

0.550.400.440.490.48

DSO (days)

145107735561

DIO (days)

257339337255232

DPO (days)

217272281273199

Cash conversion cycle (days)

1841751283794

Revenue by Region

Region (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Hong Kong

242.5281.5305.3305.5291.8

Chinese Mainland

374.1132.362.935.32.6

Other countries/regions

43.034.238.741.241.7

Total

659.6448.1406.9382.1336.1

Region YoY growth (%)

Region YoY growth (%)FY2022FY2023FY2024FY2025

Hong Kong

16.18.40.1-4.5

Chinese Mainland

-64.6-52.5-43.8-92.6

Other countries/regions

-20.413.06.51.1

Revenue by Region (FY2021–FY2024)

Healthcare products by market (HKD Mn)FY2021FY2022FY2023FY2024

United States

31.526.830.130.9

Japan

9.47.57.89.4

Hong Kong (and Mainland from FY2023)

37.144.544.144.0

Total

78.178.982.084.3

Share Price History

DatePrice (HKD)Source / context

8 Jul 2015

5.98

IPO price (etnet). Pre-2020 rights issue, so not directly comparable.

28 Dec 2022

1.28

Closing price immediately before the 29 Dec 2022 option grant (FY22 Ann.)

Feb 2025

~0.52

etnet quote, 4 Feb 2025

25 Jul 2025

0.455

Close on placement signing date (FY25 Ann.)

26 Feb 2026

0.335

Close on convertible bond signing date (IR26)

5 Jun 2026

0.30

Google Finance; 52-week range HK$0.28–0.52

20 Aug 2026

0.28

SA

9 Oct 2026

0.242

SA

Valuation Multiples

MultiplePuraPharmChina TCM (0570.HK)

Market cap

HK$129.7M

HK$7.96bn (roic.ai)

Enterprise value

≈HK$488M (equity + borrowings 314.4 + CB 19.5 + leases 36.7 − cash 12.2)

Not computed

P/E

n.m. (TTM net loss ≈HK$27.7M)

n.m. (FY25 loss)

EV/Sales (TTM revenue ≈HK$323.5M)

≈1.5x

Not computed

EV/EBITDA (TTM EBITDA ≈HK$39.4M, incl. items)

≈12.4x

Not computed

P/B (equity HK$125.0M)

≈1.04x

Not computed

P/TBV

≈3.9x (tangible equity ≈HK$41.7M)

Not computed

Dividend per share (HKD)

Dividend per share (HKD)FY2021FY2022FY2023FY2024FY2025

Ordinary DPS

00000

Bucket Details

BucketHKD K

Within 1 year or on demand

272,834

Year 2

11,831

Years 3–5

29,758

Total bank and other borrowings

314,423

Convertible bonds (HK$20M principal; matures Mar 2028, extendable to Mar 2029)

19,488 carrying value

Analyst Conclusions

Management guidance

No numerical guidance. Management expresses "measured optimism" for H2 2026. It cites GBA clinic expansion and healthcare-product growth as drivers, alongside continued cost control and refinancing (IR26).

Consensus

Not available; no coverage.

Bull case

  1. The core is profitable and cheap at the enterprise level. The integrated HK CCMG plus Nanning chain generated HK$67.4M of combined segment profit in FY2025 (analyst-computed). On a ≈HK$488M EV, a normalised EBITDA of HK$40–50M implies about 10–12x, reasonable for a near-monopoly in a defensible niche if refinancing succeeds.

  2. Cost and loss trajectory is improving. H1 2026 net loss fell 34.7% to HK$14.2M, gross margin rose to 57.8% and administrative expenses fell 20.8%. Annualising H1 cost levels suggests a path toward breakeven if revenue stabilises.

  3. Optionality. Mainland standards keep expanding (342 to 396), and PuraPharm retains a licensed, certified plant. A reopened private-hospital channel, a clinical-asset success, or a strategic or state-linked investor (Providence's principal has a Shenzhen SASAC background) could re-rate a stock trading near book value.

Bear case

  1. Liquidity could force a dilutive or distressed outcome. Cash of HK$12.2M covers 4% of current borrowings. Loans are already in default or covenant breach, and the auditor flags material uncertainty. Any lender withdrawal from RMB lines would be severe.

  2. Revenue erosion continues. Group revenue fell for a fifth straight period (H1 2026 −7.3%). The growth initiatives are faltering: e-commerce −20.4%, Shenzhen clinics halved, US −22.6%, Japan −43.3%. Meanwhile HK CCMG segment profit fell 61% in H1 2026.

  3. Governance and dilution overhang. A connected-party IP purchase was paid in shares, and the licensor's beneficial ownership is ambiguous. The chair/CEO roles are combined. Further equity raises are being sought at a share price about 44% below the October 2025 placement price.

Catalysts and monitorables (next 12 months)

  • Outcome of lender negotiations: default cure, term deferrals, covenant resets

  • Any new investor or asset disposal announcement (properties; Guizhou or Nanning assets)

  • FY2026 results (expected March 2026+1, i.e. ~March 2027), including whether the going-concern paragraph persists

  • H2 2026 HK CCMG volume and pricing; trend in inter-segment transfer pricing

  • Mainland national-standard count and any private-hospital or GBA traction

  • Use of Providence proceeds: clinical trial initiation in Hong Kong, Canadian NHP filing

  • Convertible bond conversion behaviour (conversion at HK$0.49 versus a HK$0.24 share price)

  • Clarification of BAGI Research ownership and related-party flows

  • Board stability following the 2025–2026 INED turnover

Analyst verdict

PuraPharm is a quality franchise trapped inside a fragile capital structure. Its Hong Kong CCMG business is a genuine niche leader. It claims more than 80% share, holds an unusually strong set of international quality certifications, and has delivered a 24–36% segment margin over five years. Together with the captive Nanning plant, it generated about HK$67M of segment profit in FY2025. On that measure the core business is clearly viable.

The group as a whole is not. The Mainland hospital business that once supplied more than half of revenue has gone to zero since national standards took effect. Restructuring the plantation and Mainland assets destroyed about HK$270M of book equity between FY2021 and FY2023. What remains is a roughly HK$320M revenue company carrying about HK$314M of mostly short-term RMB debt and only HK$12M of cash, with some loans in default.

Management has executed credibly on costs: S&D is down 76% and headcount 35%. It has also recapitalised modestly through the 2025 share issues and the 2026 convertible bond. But the working-capital release that funded deleveraging is exhausted, H1 2026 operating cash flow was negative, and each growth initiative is currently shrinking.

The equity is therefore a binary instrument. The upside case requires lenders to keep rolling facilities while a new strategic investor or asset sale materially de-risks the balance sheet. Under those conditions, a business trading at about 1x book and about 12x EBITDA could re-rate meaningfully. The downside case is a further heavily dilutive raise, or creditor-led restructuring, at prices well below the October 2025 placement level.

With no sell-side coverage, thin liquidity, combined chair and CEO roles, and an ambiguous related-party IP transaction, the governance discount is warranted. Verdict: speculative, special-situation profile. The core monitorable is lender behaviour, not product demand.


It is not investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAge (AR2025)TenureBackground and educationSource

Chan Yu Ling, Abraham

Founder, Chairman, CEO, Executive Director; Nomination Committee chair

65

Founder 1998

30+ years in Chinese medicine; leads R&D. Vice chairman, Chinese Medicine Granule Professional Committee, China Association of TCM. B.A.Sc., University of Toronto; Chartered Engineer (UK); P.Eng. (Ontario). Spouse of Ms. Man.

AR2025

Man Yee Wai, Viola

Executive Director (corporate and brand strategy)

60

Since 1998

Formerly Nestlé China (Key Account / Group Product Manager) and Coca-Cola China (Consumer Marketing Manager). Chairman of TWGHs (2012/13). Bronze Bauhinia Star (2013). B.Sc. (Western Ontario); MBA (Windsor).

AR2025

Dr. Tsoi Kam Biu, Alvin

Executive Director; ESG Committee chair

69

Director 2011–May 2021; re-appointed 30 Jun 2025

40+ years in sales management and Chinese medicine. Listed CMP. Doctorate in Dental Medicine (De Ocampo Memorial College); Bachelor in Chinese Medicine.

AR2025

Leung Stephen Kwok Keung

Non-executive Director

69

Appointment date not stated in reviewed filings (on the board by Feb 2025)

Pfizer 1983–2022, including Country Manager Hong Kong from 1997. B.Pharm (Liverpool John Moores); M.Bus (UMIST). Registered pharmacist (HK, UK).

AR2025

Dong Zimeng

Non-executive Director

40

Since 30 Oct 2025

Managing partner of Providence Capital Group (SFC Type 9). Former president of Shenzhen Capital International (Shenzhen SASAC-owned). M.Sc./B.Eng. (Warwick). Ultimate owner of subscriber Providence Discovery Fund.

AR2025; FY25 Ann.

Dr. Hung Ting On, John

INED; Audit Committee chair

64

Since 29 Aug 2025

Former senior partner of Deloitte Asia Pacific; vice chairman of Deloitte China. Hon. LLD and MBA (Warwick); fellow and past president, ICAEW China Chapter.

AR2025

Dr. Leung Lim Kin, Simon

INED; Remuneration Committee chair

71

Appointment date not stated in reviewed filings

Former CEO of Microsoft Greater China and president of Motorola Asia-Pacific. Vice chairman of NetDragon (0777.HK); chairman of Mynd.ai. DBA (PolyU).

AR2025

Lee Stephen

INED; Audit Committee member

—

Appointed in 2026 (exact date not disclosed in IR26)

Biography not available in reviewed documents

IR26

Prof. Ng Wang Wai, Charles

INED; Audit Committee member

—

Appointed in 2026 (exact date not disclosed in IR26)

Biography not available in reviewed documents

IR26

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleDetail

Shi Gang

VP Greater China, age 70

Joined Oct 2004; PRC regulatory and government liaison (AR2025)

Chan Charmayne

Company Secretary

ACG, HKACG (AR2025)

Anthony Siu

Senior Financial Advisor; ESG Committee member

Appointed 9 Apr 2025 (AR2025)

Kwong Kar Fai

Head of Supply Chain

ESG Committee member (AR2025)

Zhou Jian

Nanning Production Director

ESG Committee member (AR2025)

Cheung Kwun Kiu

Financial Controller

Per Yahoo Finance profile (aggregator)

CFO

No CFO disclosed

—

“—” = not publicly disclosed.

Governance Overview

FeatureStatus

Board size

9 (3 ED, 2 NED, 4 INED) after 2026 changes

Independence

4 of 9 INEDs (44%)

Chair / CEO

Combined in the founder. This is a disclosed deviation from CG Code C.2.1 (FY25 Ann.; IR26).

Committees

Audit (4 INEDs; chair Hung), Remuneration (chair Leung Simon), Nomination (chair Chan), ESG (management-level; chair Tsoi)

Family ties

CEO and ED Man are spouses

Gender diversity

1 female director of 9 (11%) after the 2026 changes (analyst-computed)

Major Shareholders

HolderShares% of 535.9M

Fullgold Development Ltd (100% Chan)

81,929,00015.29

PuraPharm Corporation Ltd (BVI; via Joint Partners Investments, owned 50/50 by Chan and Man)

76,349,75014.25

Mr. Chan (direct)

40,108,2677.48

Gold Sparkle Ltd (100% Chan)

19,576,0803.65

Ms. Man (direct)

8,226,0501.54

Chan and associates subtotal

226,189,147

42.21

The Licensor (Patent Licence Agreement; identified in IR26 as BAGI Research Limited)

93,488,37217.45

Providence Discovery Fund (Dong Zimeng)

46,512,0008.68

Dr. Tsoi (ED)

2,527,0000.47

Dr. Leung Simon (INED)

18,0000.003

Share award trust

844,3350.16

Other public

166,318,79331.04

Competitive Landscape

Key Competitors

CompetitorSegment overlapRevenue (latest)Positioning vs PuraPharm

China Traditional Chinese Medicine Holdings (0570.HK; Sinopharm subsidiary; brands Tianjiang and Yifang)

Mainland CCMG; also HK presence

FY2025 group revenue RMB14.74bn (−10.7%); CCMG RMB6.10bn (−12.5%); net loss RMB0.46bn (HKEX FY2025 results)

Mainland CCMG leader at roughly 160x PuraPharm's scale; also squeezed by centralised procurement

China Resources Sanjiu (000999.SZ)

Mainland CCMG, OTC

—

State-backed scale player in CCMG and OTC

Beijing Tong Ren Tang group (incl. 1666.HK / 3613.HK)

HK and Mainland TCM retail, clinics, OTC

—

Heritage brand with HK retail and clinic footprint; competes in clinics and health products

Eu Yan Sang (private)

HK TCM retail, clinics, health products

—

Strong HK consumer brand; direct clinic and OTC rival

Wai Yuen Tong Medicine (0897.HK)

HK proprietary Chinese medicine, health products

—

Local HK consumer TCM brand

Sun Ten Pharmaceutical (Taiwan)

Granule exports to HK and overseas

—

Taiwanese granule competitor in HK private-practitioner and export markets

Kaiser Pharmaceutical (Taiwan)

Granules (HK, overseas)

—

Same

KPC Herbs, Mayway, Evergreen Herbs (US)

US herbal formulas vs KAN

—

US practitioner-market rivals to KAN Herb

Japanese health-food makers (various)

Japan health foods vs SODX

—

Fragmented market

University-affiliated and NGO TCM clinics in HK

Clinics

—

Low-cost competition for consultations

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricPuraPharm (1498.HK)China TCM (0570.HK)

Revenue

HK$336.1M

RMB14,744.8M

Revenue growth YoY (%)

-12.0-10.7

Gross margin (%)

53.648.1

CCMG segment revenue growth (%)

HK -7.4; China -100

-12.5

Net result

Loss HK$35.2M

Loss RMB0.46bn

R&D / revenue (%)

4.1

3.5 (RMB511.5M per SA/S&P)

Recent Developments

The window is extended back to January 2025 to capture the capital restructuring.

Company Snapshot

$43.1M

Revenue

460

Employees

1998

Founded

New Territories, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Dominant HK franchise. HK CCMG revenue was HK$192.3M (57.2% of group) in FY2025, with a claimed >80% market share (AR2025).
  • Profitable core. HK CCMG segment result was HK$47.2M (FY25) and HK$68.7M (FY24), a 24.5–33.1% margin (FY25/FY24 Ann.).
  • Stable gross margin. 53.2–53.7% in FY2023–FY2025, rising to 57.8% in H1 2026 (IR26).
  • Rare quality certifications. TGA GMP (2010), USP verifications (2009, 2014), CNAS ISO 17025 laboratory (AR2025).
  • Demonstrated cost discipline. S&D down from HK$220.0M (FY21) to HK$52.5M (FY25); headcount down from 675 to 441.
  • Asset backing for borrowing. HK$157.9M of non-pledged PRC long-term assets were available as collateral at 30 Jun 2026 (IR26 note 2).

Weaknesses

  • Liquidity. Current ratio 0.47; cash HK$12.2M against current borrowings of HK$272.8M (IR26).
  • Defaults and covenant breaches. HK$24.4M in repayment default and HK$25.2M in covenant breach (FY25 Ann.); HK$53.5M non-compliant at Jun 2026 (IR26 note 14).
  • Five consecutive annual losses. Cumulative FY2021–FY2025 net loss of HK$418.8M (analyst-computed).
  • Concentration. Hong Kong was 86.8% of FY2025 revenue.
  • Loss-making clinics. Segment loss of HK$9.6M in FY2025 and HK$5.0M in H1 2026.
  • Governance. Combined chair/CEO; founder-family control; connected-party IP transaction; one female director of nine.

Opportunities

  • More Mainland national standards. The count rose from 342 (end-2024) to 396 (end-2025). Further additions could reopen hospital and private-hospital channels for a licensed, certified producer (FY25 Ann.).
  • Underused Nanning capacity. The 65,968 sq m planned smart-factory GFA could support CDMO/OEM or export volumes. This is an analyst inference; no plan has been announced.
  • Clinical pipeline. The 2025 patents fund HK, Canadian and US registration pathways (FY25 Ann. use of proceeds).
  • New investors. Providence (8.68%), the licensor (17.45%) and Protoss (convertible bond) broaden the shareholder base. Management is seeking further investors (IR26).
  • GBA integration and cross-border e-commerce. FY2025 healthcare-product growth of +9.8% was attributed to the Mainland online channel.
  • Asset monetisation. Management states it may dispose of properties if needed (FY25 Ann. going-concern measure (e)).

Threats

  • Lender action. HK$49.6M of borrowings could be subject to immediate repayment at lenders' discretion (FY25 Ann.).
  • Centralised procurement pressure. China TCM's CCMG margin contracted 3.1 points in FY2025, evidence of sector-wide pricing pressure.
  • Hong Kong consumption slowdown. Clinics −9.0% and HK CCMG −7.4% in FY2025.
  • RMB debt exposure. RMB271.3M-equivalent of borrowings against HK$-denominated revenue; no hedging (IR26).
  • Climate and raw-herb supply risk. Identified as acute and chronic risks to herb yields and costs (AR2025 ESG).
  • Further dilution. The convertible bond (up to 40.8M shares) plus a possible new equity raise at a share price well below the HK$0.43 placement price.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Jan 2025Cayman court hearing scheduled to confirm capital reduction (TipRanks)Prerequisite for restructuring
Feb–Mar 2025Capital reduction effective: par cut to US$0.001. TipRanks indicated expected effect around 24 Feb 2025; IR26 dates it to March 2025.HK$303.8M offset against accumulated losses
19 Mar 2025Inside-information update on FY2024 financial performancePreliminary results signal
Mar 2025Board meeting postponed from 27 to 28 Mar to finalise FY2024 resultsReporting-process strain
31 Mar 2025FY2024 results: revenue −6.1% to HK$382.1M; net loss HK$35.4M (FY23: HK$106.1M); going-concern material uncertainty; HK$88.4M of borrowings in covenant breachLoss narrows; liquidity flagged
9 Apr 2025Anthony Siu appointed to ESG Committee (Senior Financial Advisor)Finance bench strengthened
27 May 2025AGMRoutine
11 Jun 2025Share option scheme (adopted 2015) lapsesNo new option grants possible
30 Jun 2025Dr. Tsoi Kam Biu re-appointed ED and ESG chair; Dr. Norimoto steps down from ESG Committee; Ms. Man and Dr. Leung Simon join Nomination CommitteeBoard refresh
4 Jul 2025INED and Audit chair Ho Kwok Wah, George resignsTemporary audit-chair vacancy
25 Jul 2025Patent Licence Agreement (connected) and Providence subscription signed at HK$0.43 per share (close HK$0.455)Equity recapitalisation
26 Aug 2025H1 2025 results: revenue −17% to HK$172.3M; GM 55.2%; finance costs −30.8%Sharp first-half decline
29 Aug 2025Dr. Hung Ting On, John (ex-Deloitte China vice chairman) appointed INED and Audit chairAudit oversight strengthened
3 Oct 2025Circular on licence and subscriptionDisclosure
24 Oct 2025EGM approves both transactionsApproval
30 Oct 2025Completion: shares rise to 535.9M; Chan group to 42.21%; Dong Zimeng appointed NEDOwnership broadened; ~35% dilution
2025One new GBA clinic opened, bringing Shenzhen to 4GBA expansion
22 Feb 2026Share award scheme lapsesIncentive tools expired
26 Feb 2026HK$20M convertible bond agreement with Protoss Global Opportunities Fund (conversion HK$0.49, a 46% premium to the HK$0.335 close)Liquidity
23 Mar 2026Convertible bond completedHK$19.85M net
25 Mar 2026FY2025 results: revenue −12.0% to HK$336.1M; net loss HK$35.2M; China CCMG at zero; going-concern uncertainty; HK$24.4M loans in repayment default and HK$25.2M in covenant breachLiquidity stress intensifies
23 Apr 20262025 Annual Report published, claiming >80% HK CCMG shareDisclosure
27 May 2026AGMRoutine
25 Jun 2026INED Prof. Tsui Lap Chee resignsLoss of high-profile independent
2026 (date n/d)Lee Stephen and Prof. Ng Wang Wai, Charles appointed INEDsBoard independence restored to 4
H1 2026Shenzhen clinics reduced from 4 to 2GBA strategy setback
26 Aug 2026H1 2026 results: revenue −7.3%; GM 57.8%; net loss HK$14.2M (−34.7%); operating cash flow −HK$1.3M; HK$53.5M of borrowings non-compliant with covenantsLoss narrowing; cash flow weak
21 Sep 2026Interim Report 2026 publishedDisclosure
9 Oct 2026Share price HK$0.242, roughly half the HK$0.43 placement priceMarket scepticism

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 659.6 Mn in FY2021 to HKD 336.1 Mn in FY2025.
PuraPharm Corporation Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue659.6448.1406.9382.1336.1
Cost of sales236.2185.4190.2176.9156
Gross profit423.4262.7216.6205.1180.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.